Lipid-based nanoparticles for photosensitive drug delivery systems. [PDF]
Shim G, Jeong S, Oh JL, Kang Y.
europepmc +1 more source
Autoantigen mRNA‐LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity
Systemic and intramuscular delivery of autoantigen mRNA via lipid nanoparticles reprograms antigen‐presenting cells toward a mature, homeostatic state, driving antigen‐specific T cell exhaustion and providing therapeutic efficacy across autoimmune disease models.
Paulien Baeten +30 more
wiley +1 more source
Evaluating cell cycle- and autophagy-associated cellular accumulation of lipid-based nanoparticles. [PDF]
Wang Y +10 more
europepmc +1 more source
Lipid-Based Nanoparticles as a Pivotal Delivery Approach in Triple Negative Breast Cancer (TNBC) Therapy. [PDF]
Chaudhuri A +7 more
europepmc +1 more source
Cartilage injury promotes local fibrinogen deposition, which accelerates monosodium urate crystallization and activates integrin‐mediated matrix‐degradation. This self‐amplifying cycle drives gout‐related cartilage erosion. Disrupting fibrinogen deposition or restoring the cartilage barrier could interrupt this vicious cycle.
Hanlin Xu +7 more
wiley +1 more source
Drug delivery strategies with lipid-based nanoparticles for Alzheimer's disease treatment. [PDF]
Jang YJ +9 more
europepmc +1 more source
Trypsinogen‐loaded nanoparticles reprogram TAMs via NF‐κB/NLRP3, driving M2→M1 conversion and potent phagocytosis to unleash antitumor immunity. ABSTRACT Although reprogramming tumor‐associated macrophages (TAMs) represents a promising therapeutic strategy, approaches that are both precise and safe remain scarce.
Lei Cao +7 more
wiley +1 more source
Formulation of Lipid-Based Nanoparticles for Simultaneous Delivery of Lapatinib and Anti-Survivin siRNA for HER2+ Breast Cancer Treatment. [PDF]
Eljack S +4 more
europepmc +1 more source
A highly sensitive SERS‐based platform measures PD‐L1 expression on EpCAM+ circulating EVs from cancer patients undergoing immunotherapy. Monitoring dynamic changes after treatment reveals that reduced EpCAM+ EV PD‐L1 levels associate with improved long‐term clinical outcomes, establishing a non‐invasive approach for tracking immune checkpoint ...
Byeonggeol Mun +15 more
wiley +1 more source
Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation. [PDF]
Ilić T +6 more
europepmc +1 more source

